Drugs / LUCAR-20S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04176913 | Dec 2020 → Dec 2021 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUCAR-20S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04176913 ↗ |
| Modality | Cell therapy | “LUCAR-20S CAR-T cells” NCT04176913 ↗ |